Scopolamine Hydrobromide CAS: 114-49-8

CAS NO: 114-49-8
Scopolamine Hydrobromide
Chemical Name: Scopolamine hydrobromide
Molecular Formula: C17H21NO4.BrH
Formula Weight: 384.26
CAS No.: 114-49-8
Description Review
Description

Scopolamine Hydrobromide is a medication used to treat motion sickness, nausea, and vomiting. It is also used in anesthesia to reduce secretions and prevent bradycardia.

Chemical Name:

The chemical name of Scopolamine Hydrobromide is (1alpha,2beta,4beta,5alpha,7beta)-7-(3-hydroxy-2-phenylpropionyloxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0(2,4)]nonane bromide.

Molecular Formula:

The molecular formula of Scopolamine Hydrobromide is C17H22BrNO4.

Formula Weight:

The formula weight of Scopolamine Hydrobromide is 384.27 g/mol.

CAS No:

The CAS number of Scopolamine Hydrobromide is 114-49-8.

Top Ten Keywords from Google and Synonyms:

  1. Motion sickness treatment
  2. Scopolamine Hydrobromide
  3. Anticholinergic medication
  4. Nausea and vomiting relief
  5. Anesthesia drug
  6. Secretion reduction agent
  7. Bradycardia prevention
  8. Muscarinic receptor antagonist
  9. Parasympatholytic drug
  10. Antiemetic medication

Synonyms: Hyoscine Hydrobromide, L-Hyoscyamine Hydrobromide, Scopoderm, Buscapina

Health Benefits of Scopolamine Hydrobromide:

Scopolamine Hydrobromide is primarily used to treat motion sickness, nausea, and vomiting. It helps in reducing symptoms such as dizziness, headaches, and gastrointestinal upset. Additionally, it can be used in anesthesia to reduce secretions and prevent bradycardia.

Potential Effects:

Scopolamine Hydrobromide is an anticholinergic medication that works by blocking the effects of acetylcholine on the muscarinic receptor sites. By doing so, it reduces the activity of the parasympathetic nervous system, leading to reduced secretions, decreased gastrointestinal motility and relief from symptoms of motion sickness, nausea, and vomiting. This medication can also have an effect on the cardiovascular system, producing tachycardia and hypertension.

Product Mechanism:

Scopolamine Hydrobromide works by selectively inhibiting the activity of the muscarinic receptors, which are responsible for the actions of acetylcholine on the parasympathetic nervous system. By blocking this pathway, Scopolamine Hydrobromide reduces the formation of inflammatory mediators and provides relief from pain and inflammation. The exact mechanism of action is complex, and the effects of Scopolamine Hydrobromide can vary depending on the dose and route of administration.

Safety:

Scopolamine Hydrobromide is generally considered safe when used as directed. However, like all medications, it may cause side effects in some people. It is not recommended for certain patients, such as those with narrow-angle glaucoma, obstructive uropathy, or ulcerative colitis. It should also be used with caution in people with asthma, pregnancy, or lactation.

Side Effects:

Common side effects of Scopolamine Hydrobromide include dry mouth, blurred vision, and urinary retention. Rare but serious side effects may include tachycardia, hypertension, and confusion. Patients who experience any of these symptoms should seek immediate medical attention.

Dosing Information:

The recommended dose of Scopolamine Hydrobromide depends on the condition being treated and the individual patient's response to the medication. For motion sickness, the usual dose is 0.3-0.6 mg administered transdermally every 3 days as needed. In anesthesia, the recommended dose is typically 0.3-0.6 mg administered intravenously or intramuscularly.

Conclusion:

Scopolamine Hydrobromide is a medication used to treat motion sickness, nausea, and vomiting. It works by blocking the effects of acetylcholine on the muscarinic receptor sites, leading to reduced secretions, decreased gastrointestinal motility and relief from symptoms. While it is generally safe and effective, it may cause side effects in some patients and is not recommended for certain populations. If you have any questions about Scopolamine Hydrobromide or its use, please consult your healthcare provider

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code